I know that it doesn't look possible based on my youthful vigour, but my wife and I celebrated our 25th wedding anniversary recently. If...

In this first Data Insight report we analyse Hospital Episode Statistics data to understand the impact COVID-19 had at one major UK...

Digital healthcare is not new, but the further future potential is fascinating. Since the 1980s, technology has driven broad and deep...

Key Account Management (KAM) is one of the most enduring buzz-phrases in UK pharmaceutical industry. Such has been the fervour around the...

Digital healthcare is not ‘new’ - since the 1980’s, technology has driven broad and deep health service transformation, and health tech...

Digital health can bring broad and profound benefits to the life sciences industry. Yet, these new and emerging technologies are...

Simulation has been used for many years by other industries to identify efficiencies in processes and systems but now the health sector...

There are many reasons to embed digital care within patient pathways. Patients, clinicians, and service providers can all benefit. But,...

We're working with two major trusts to improve their ability to “catch up” with the backlog after Covid-19 by moving some services into...

We have just been published (again!!). A poster on our analysis of the severe liver disease pathway was presented at the British...

We recently analysed the lung cancer pathway. Data confirmed that during 2020-2021, most likely attributed to Covid-19, there was a...

The NHS is data rich, in fact many countries look at the UK with envious eyes when it comes to the volume and quality of our data. But...

Existing commercial models of UK pharmaceutical companies need to change. NHS organisations have a clearly defined mandate to get the...

Myeloma – the problem in need of a solution Once upon a time, we would have considered the diagnosis of multiple myeloma as a death...